San Diego Union-Tribune Examines Financial Health of Immune Response Corp.
The Immune Response Corp., the developer of Remune, an experimental therapeutic vaccine used to treat AIDS, is "near bankruptcy" and has only enough money to fund operations for a few more weeks, the San Diego Union-Tribune reports. The company, which was founded by the late Jonas Salk, is trying to "lure new investors" or start a research partnership with another company to avoid going out of business. The Union-Tribune reports that Immune Response's "best shot at survival" would be the approval of Remune to treat AIDS patients in Thailand, but the outlook for the vaccine "appears bleak" (Crabtree, San Diego Union-Tribune, 6/2). The full article is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.